These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33616089)

  • 1. Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo.
    Volckmar J; Knop L; Hirsch T; Frentzel S; Erck C; van Ham M; Stegemann-Koniszewski S; Bruder D
    J Vis Exp; 2021 Feb; (168):. PubMed ID: 33616089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells.
    Volckmar J; Knop L; Stegemann-Koniszewski S; Schulze K; Ebensen T; Guzmán CA; Bruder D
    Vaccine; 2019 Aug; 37(35):4963-4974. PubMed ID: 31320219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
    Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
    J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in cis but only have partial targeting specificity.
    Kreutz M; Giquel B; Hu Q; Abuknesha R; Uematsu S; Akira S; Nestle FO; Diebold SS
    PLoS One; 2012; 7(7):e40208. PubMed ID: 22808118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination.
    Bonifaz LC; Bonnyay DP; Charalambous A; Darguste DI; Fujii S; Soares H; Brimnes MK; Moltedo B; Moran TM; Steinman RM
    J Exp Med; 2004 Mar; 199(6):815-24. PubMed ID: 15024047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.
    Grossmann C; Tenbusch M; Nchinda G; Temchura V; Nabi G; Stone GW; Kornbluth RS; Uberla K
    BMC Immunol; 2009 Aug; 10():43. PubMed ID: 19650904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the vaccine potential of Dec-205 targeting in Mycobacterium tuberculosis infection in mice.
    Stylianou E; Pepponi I; van Dolleweerd CJ; Paul MJ; Ma JK; Reljic R
    Vaccine; 2011 Mar; 29(12):2279-86. PubMed ID: 21272603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of rotavirus VP6 to DEC-205 induces protection against the infection in mice.
    Badillo-Godinez O; Gutierrez-Xicotencatl L; Plett-Torres T; Pedroza-Saavedra A; Gonzalez-Jaimes A; Chihu-Amparan L; Maldonado-Gama M; Espino-Solis G; Bonifaz LC; Esquivel-Guadarrama F
    Vaccine; 2015 Aug; 33(35):4228-37. PubMed ID: 25850020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the antigen encoded by adenoviral vectors to the DEC205 receptor modulates the cellular and humoral immune response.
    Tenbusch M; Nchinda G; Storcksdieck genannt Bonsmann M; Temchura V; Überla K
    Int Immunol; 2013 Apr; 25(4):247-58. PubMed ID: 23184617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation.
    Birkholz K; Schwenkert M; Kellner C; Gross S; Fey G; Schuler-Thurner B; Schuler G; Schaft N; Dörrie J
    Blood; 2010 Sep; 116(13):2277-85. PubMed ID: 20566893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DEC-205 receptor-mediated long-circling nanoliposome as an antigen and
    Feng H; Yang X; Fan J; Zhang L; Liu Q; Chai D
    Drug Deliv; 2020 Dec; 27(1):1581-1596. PubMed ID: 33169636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting dendritic cells in humanized mice receiving adoptive T cells via monoclonal antibodies fused to Flu epitopes.
    Graham JP; Authie P; Yu CI; Zurawski SM; Li XH; Marches F; Flamar AL; Acharya A; Banchereau J; Palucka AK
    Vaccine; 2016 Sep; 34(41):4857-4865. PubMed ID: 27595442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted antigen delivery to dendritic cells elicits robust antiviral T cell-mediated immunity in the liver.
    Volckmar J; Gereke M; Ebensen T; Riese P; Philipsen L; Lienenklaus S; Wohlleber D; Klopfleisch R; Stegemann-Koniszewski S; Müller AJ; Gruber AD; Knolle P; Guzman CA; Bruder D
    Sci Rep; 2017 Mar; 7():43985. PubMed ID: 28266658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study.
    Cruz LJ; Rosalia RA; Kleinovink JW; Rueda F; Löwik CW; Ossendorp F
    J Control Release; 2014 Oct; 192():209-18. PubMed ID: 25068703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of innate and adaptive immunity by delivery of poly dA:dT to dendritic cells.
    Barbuto S; Idoyaga J; Vila-Perelló M; Longhi MP; Breton G; Steinman RM; Muir TW
    Nat Chem Biol; 2013 Apr; 9(4):250-6. PubMed ID: 23416331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting DEC-205
    Tabansky I; Keskin DB; Watts D; Petzold C; Funaro M; Sands W; Wright P; Yunis EJ; Najjar S; Diamond B; Cao Y; Mooney D; Kretschmer K; Stern JNH
    Mol Med; 2018 May; 24(1):17. PubMed ID: 30134798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells.
    Do Y; Park CG; Kang YS; Park SH; Lynch RM; Lee H; Powell BS; Steinman RM
    Eur J Immunol; 2008 Jan; 38(1):20-9. PubMed ID: 18081041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV gag protein is efficiently cross-presented when targeted with an antibody towards the DEC-205 receptor in Flt3 ligand-mobilized murine DC.
    Bozzacco L; Trumpfheller C; Huang Y; Longhi MP; Shimeliovich I; Schauer JD; Park CG; Steinman RM
    Eur J Immunol; 2010 Jan; 40(1):36-46. PubMed ID: 19830741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.
    Wang B; Kuroiwa JM; He LZ; Charalambous A; Keler T; Steinman RM
    Ann N Y Acad Sci; 2009 Sep; 1174():6-17. PubMed ID: 19769731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
    Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
    Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.